Newest studies

Small-Data Deep Learning for Alzheimer-Spectrum Classification from Structural MRI: A Feasibility Study Using OASIS

42/100 ✓ Peer-reviewed Brain scans and imaging Journal of Imaging

Key finding: The from-scratch CNN recovered only a broad normal-versus-impaired signal (CN vs. any impairment AUC 0.59) and was at chance on adjacent-stage tasks (MCI vs.

• Brain Scans
• Digital Tools
• Early Stage

Full summary, score breakdown and related studies → Original source

Diagnostic Accuracy of the Boston Criteria v2.0 in Memory Clinic Patients

45/100 ✓ Peer-reviewed Getting a diagnosis Neurology

Key finding: Eighty patients were included (mean age: 81 years, interquartile range 74-86 years; 36.2% female, ∼80% with dementia and Alzheimer disease). +4 more findings

• Diagnosis
• Care Services

Full summary, score breakdown and related studies → Original source

Genetic Modifiers of ABCA1 Activity Interact with APOE Isoforms to Mediate Alzheimer's Disease Risk

43/100 ✓ Peer-reviewed Genetics Annals of Neurology

Key finding: Damaging nonsynonymous ABCA1 variants had differential AD risk effects between APOE genotype groups and exhibited interaction effects with APOE ε2 and ε4. +4 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Predicting Alzheimer progression using EEG-based digital twins

39/100 ✓ Peer-reviewed Genetics npj Digital Medicine

Key finding: Digital biomarkers demonstrated strong prognostic value, predicting participants who converted at follow-up, significantly outperforming standard EEG metrics. +1 more finding

• Genetics
• Biomarkers
• Brain Scans

Full summary, score breakdown and related studies → Original source

Blood Biomarkers of Alzheimer Disease and Rates of Global and Domain-Specific Cognitive Decline

53/100 ✓ Peer-reviewed Tau biomarkers JAMA network open

Key finding: Moreover, there is limited knowledge regarding associations with domain-specific cognitive decline and modifying effects of key individual characteristics. +3 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Multi-dimensional attention framework for personalised Alzheimer's disease progression prediction across sporadic and genetic risk cohorts

16/100 ⚠ Preprint — not yet peer-reviewed Down syndrome and Alzheimer's Research Square

Key finding: Alzheimer's disease progresses heterogeneously across diverse cohorts, yet current predictive models fail to capture this complexity while remaining clinically interpretable. +3 more findings

• Genetics

Scored 37 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Variation in Medicare Part D and Part B drug spending among older adults with Alzheimer's disease and related dementias

44/100 ✓ Peer-reviewed Costs and economics Innovation in Aging

Key finding: Medicare Part D drug spending was substantial, increasing with dual-eligibility duration: $8732-$9107 among beneficiaries with full-year dual eligibility and exceeding $11 500 among those with 5+ chronic conditions.

• Policy
• Treatments

Full summary, score breakdown and related studies → Original source

Plasma Alzheimer Biomarkers and Diagnostic Decision-Making in Memory Clinics

52/100 ✓ Peer-reviewed Biomarkers JAMA Network Open

Key finding: Among 356 patients (79%) with AD as the primary suspected etiology, assessment of BBM classified 149 patients (42%) as high, 101 patients (28%) as intermediate, and 106 patients (30%) as low probability of AD. +4 more findings

• Biomarkers
• Diagnosis
• Brain Scans

Full summary, score breakdown and related studies → Original source

A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results

57/100 ✓ Peer-reviewed Treatments Age and ageing

Key finding: In this real-life crossover study, THC/CBD oil did not show superiority over placebo in reducing agitation in severe dementia. +3 more findings

• Clinical Trials
• Treatments

Full summary, score breakdown and related studies → Original source

Sleep duration and mental well-being are associated with delayed memory in a 12-week digital and remote community-sample study

16/100 ⚠ Preprint — not yet peer-reviewed Risk factors medRxiv

Key finding: Sleeping more than one’s usual average the night before testing was associated with better delayed memory ( β = 0.03, p = 0.02), while no between-person sleep effects emerged. +4 more findings

• Lifestyle
• Digital Tools

Scored 39 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Cost-effectiveness of amyloid-targeting therapies in a memory clinic population; a simulation study

16/100 ⚠ Preprint — not yet peer-reviewed Treatments medRxiv

Key finding: The cost-effectiveness of ATTs is strongly influenced by the waning of the treatment effect.

• Treatments
• Policy

Scored 27 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Consensus Risk Modeling and Uncertainty Quantification of Alzheimer’s Disease Using 5ADCSI Plasma Biomarkers and Multiple External Machine-Learning Frameworks

16/100 ⚠ Preprint — not yet peer-reviewed Biomarkers medRxiv

Key finding: All three frameworks recognized biologically coherent AD-related signal despite differences in training cohort and assay methodology.

• Biomarkers

Scored 32 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Heterogeneity in Multimodal AI Feature Engineering Utility for Explaining Change in Dementia

16/100 ⚠ Preprint — not yet peer-reviewed Cognitive tests and assessment PsyArXiv

Key finding: Open-weight largelanguage models (LLMs) are employed (collaborative inference from eight labs) for AI magneticresonance imaging (MRI) insight extraction and compared in terms of relative feature importance(between-model, between-feature) at the AI-engineered parameter-level (along with other engineeredmeta-features) for relative explanatory utility with regard to participant change in an assessment of mildcognitive impairment (MCI) and dementia. +4 more findings

• Digital Tools

Scored 21 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Plasma p-tau217 detects Alzheimer's disease co-pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort

57/100 ✓ Peer-reviewed Brain tissue and pathology Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: Among CAA participants, 29 met CSF criteria for AD co-pathology. +3 more findings

• Biomarkers
• Diagnosis

Full summary, score breakdown and related studies → Original source

APOE-guided lecanemab dosing dissociates ARIA-E from ARIA-H: The K-ROAD study

66/100 ✓ Peer-reviewed Treatments Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: ARIA-E incidence was 2.0% in non-carriers and 6.2% in εε4/εε4 homozygotes (εε4/εε4-versus-non-carrier OR 3.25, versus 8.49 in Clarity AD and 8.32 in Japan post-marketing surveillance). +3 more findings

• Genetics
• Treatments
• Side Effects

Full summary, score breakdown and related studies → Original source

Gantenerumab for Early Alzheimer's Disease: An Updated Systematic Review and Meta-Analysis

89/100 ✓ Peer-reviewed Treatments Brain and behavior

Key finding: Six trials (3103 Gantenerumab significantly reduces amyloid and statistically improves select functional (FAQ) and cognitive (ADAS-Cog13) measures in early AD; however, these changes remain below accepted MCID thresholds, indicating a lack of true clinical meaningfulness. +1 more finding

Full summary, score breakdown and related studies → Original source

Heterogeneity in plasma p-tau217 response and its association with cognitive trajectories under lecanemab treatment

73/100 ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: Plasma p-tau217 levels decreased significantly from 3 months, with the greatest decline between 3 and 6 months, followed by a plateau. +4 more findings

• Biomarkers
• Treatments

Full summary, score breakdown and related studies → Original source

Optimized plasma p-tau217 and p-tau217/Aβ42 cutoffs enhance detection of pre-clinical Alzheimer's disease across diverse participants

61/100 ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: Among 191 participants (57 Black, 46 Hispanic White, 88 non-Hispanic White), age-adjusted plasma p-tau217 and p-tau217/Aβ42 performed similarly in detecting amyloid-positive individuals (≥ 25 Centiloids), regardless of race/ethnicity. +4 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Biomarker-Based Diagnosis and Care Pathways for Alzheimer's Disease in the Era of Disease-Modifying Treatments: A Consensus Statement by Belgian Experts

32/100 ✓ Peer-reviewed Health systems and care delivery European journal of neurology

Key finding: The consensus outlines a stepwise diagnostic approach that integrates clinical assessment with biomarker confirmation using cerebrospinal fluid, amyloid-PET, and emerging blood-based tests. +4 more findings

• Treatments
• Biomarkers
• Care Services

Full summary, score breakdown and related studies → Original source

Real-World Evidence of GLP-1 Receptor Agonist in Neurodegenerative Disorder: A Scoping Review of Observational Studies

31/100 ✓ Peer-reviewed Drug development Open Science Framework

Key finding: Consequently, drug repurposing has emerged as a crucial strategy, with Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs) such as exenatide, liraglutide, semaglutide; gaining significant attention.

• Treatments

Full summary, score breakdown and related studies → Original source

Geographical variation in key outcomes in new Danish health councils

36/100 ✓ Peer-reviewed Risk factors Danish Medical Journal

Key finding: Among 5.98 million inhabitants, GP contacts and primary care costs showed limited variation (bCV 0.8% and 4.7%). +4 more findings

Full summary, score breakdown and related studies → Original source

Functional assessment improves discrimination of clinical and biomarker-defined Alzheimer’s disease

16/100 ⚠ Preprint — not yet peer-reviewed Disparities medRxiv

Key finding: In a contemporary, diverse cohort, most established dementia risk algorithms had limited power in discriminating amyloid positivity, pTau-217 positivity, and current cognitive status despite acceptable calibration. +2 more findings

• Biomarkers
• Risk Factors

Scored 35 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Determining the metabolic profile measured using ultra-high pressure liquid chromatography associated with Beta Amyloid burden in the brain in individuals with mild cognitive impairment

16/100 ⚠ Preprint — not yet peer-reviewed Brain scans and imaging Research Square

Key finding: Understanding the metabolic alterations associated with amyloid load can pave the way for future research incorporating metabolites into a therapeutic treatment that can be identified as crucial to the illness’s progression.

• Brain Scans
• Early Stage

Scored 27 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

APOEε4 attenuates early TREM2-mediated microglial responses and influences disease trajectories in dementia with Lewy bodies

16/100 ⚠ Preprint — not yet peer-reviewed TREM2 and immune genetics Research Square

Key finding: Using a specific immunoassay targeting cleaved soluble TREM2 (sTREM2), we investigated TREM2-dependent microglial responses across two independent DLB cohorts (n = 129) with molecular biomarker profiling and longitudinal follow-up. sTREM2 showed stage-dependent associations with AD-related biomarkers, being associated with amyloid-related changes during prodromal DLB and predominantly to tau-related markers at dementia stage. +3 more findings

• Genetics
• Other Dementias
• Brain Biology

Scored 44 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Association of total and brain-derived Alzheimer’s disease plasma biomarkers with brain amyloid deposition in a community-based sample

16/100 ⚠ Preprint — not yet peer-reviewed Biomarkers medRxiv

Key finding: Bidirectional stepwise linear regression analysis was performed to identify plasma biomarkers associated with brain Aβ deposition. +4 more findings

• Biomarkers

Scored 44 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source